Read by QxMD icon Read


Xuesong Han, Ahmedin Jemal, Erin Hulland, Edgar P Simard, Loretta Nastoupil, Elizabeth M Ward, Christopher R Flowers
BACKGROUND: Highly active antiretroviral therapy (HAART) has extended the life expectancy of HIV/AIDS patients to approach that of the general population. However, it remains unclear whether HIV infection affects the survival of lymphoma patients in the HAART era. METHODS: Patients diagnosed with Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), peripheral T-cell lymphoma (PTCL) or follicular lymphoma (FL) during 2004-2011 were identified from the National Cancer Database...
October 18, 2016: Cancer Epidemiology, Biomarkers & Prevention
Neta Goldschmidt, Fares Darawshy, Geffen Kleinstern, Elena Slyusarevsky, Galina Pogrebijski, Svetlana Krichevsky, Dina Ben-Yehuda, Moshe E Gatt
We retrospectively studied the prognostic role of molecular (gene rearrangement, GRR) bone marrow (BM) involvement in diffuse large B-cell lymphoma (DLBCL, 424 patients) and in peripheral T-cell lymphoma (PTCL, 67 patients). When correlating BM GRR to histological findings at diagnosis, the GRR test was more sensitive (p = 0.036) but less specific (p < 0.0001) in PTCL than in DLBCL. For DLBCL (but not PTCL), a positive BM GRR correlated with advanced stage (p = 0.0001) and high IPI (p = 0...
October 18, 2016: Leukemia & Lymphoma
Anne-Segolene Cottereau, Sebastien Hapdey, Loic Chartier, Romain Modzelewski, Olivier Casasnovas, Emmanuel Itti, Herve Tilly, Pierre Vera, Michel A Meignan, Stéphanie Becker
: To compare in a large series of Peripheral T cell lymphoma (PTCL), as a model of diffuse disease, the prognostic value of baseline Total Metabolic Tumor Volume (TMTV) measured on FDG-PET/CT with adaptive thresholding methods to TMTV measured with a fixed 41% SUVmax threshold method. METHODS: 106 patients with PTCL, staged with a PET/CT were enrolled from 5 LYSA centers. In this series TMTV computed with the 41% SUVmax threshold is a strong predictor of outcome (Ann Oncol, 2016)...
October 6, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Atsushi Kobayashi, Shiori Oizumi, Yasuhiro Shigeta, Masaki Yoshida, Masako Kato
We synthesized a carboxy-substituted Pt(ii)-terpyridine complex, i.e. [PtCl(Hctpy)]Cl ([1H]Cl; Hctpy = 4'-carboxy-2,2':6',2''-terpyridine), that shows interesting switchable vapochromic behaviour upon protonation/deprotonation of the carboxy group. The as-synthesized dark-blue amorphous-like solid [1H]Cl·3H2O was converted to a yellow crystalline solid, [1H]Cl·H2O, upon exposure to various polar organic solvent vapours (e.g., acetonitrile, ethanol, 1-propanol, and dichloromethane), which promote the removal of water molecules...
October 14, 2016: Dalton Transactions: An International Journal of Inorganic Chemistry
Christine E Cutucache, Tyler A Herek
Currently, there are 19 different peripheral T-cell lymphoma (PTCL) entities recognized by the World Health Organization; however, ~70% of PTCL diagnoses fall within one of three subtypes [i.e., peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma, and angioimmunoblastic T-cell lymphoma]. PTCL-NOS is a grouping of extra-thymic neoplasms that represent a challenging and heterogeneous subset of non-Hodgkin's lymphomas. Research into peripheral T-cell lymphomas has been cumbersome as the lack of defining cytogenetic, histological, and molecular features has stymied diagnosis and treatment of these diseases...
2016: Frontiers in Oncology
Z Wang, D B Zhang, W Zhou
Objective: To evaluate the expression of transcription factor T-bet (T-box expressed in T cells) and explore its effects on prognosis in peripheral T-cell lymphoma (PTCL). Methods: This study included 109 previously untreated patients diagnosed with PTCL in the pathology system at Peking Union Medical College Hospital from 2007 to 2013. Formalin-fixed, paraffin-embedded blocks and clinical information of these patients were collected. T-bet expression was examined by immunohistochemical stain, while its relationship with clinical feature and prognosis was analyzed...
September 14, 2016: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Ya-Ting Yang, Cheng-Jeng Tai, Chiehfeng Chen, Hong-Cheng Wu, Natalia Mikhaylichenko, Hsien-Tsai Chiu, Yun-Yi Chen, Yi-Hsin Elsa Hsu
BACKGROUND: The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL. METHOD: The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL...
2016: PloS One
Staci L Haney, G Michael Upchurch, Jana Opavska, David Klinkebiel, Ryan A Hlady, Sohini Roy, Samikshan Dutta, Kaustubh Datta, Rene Opavsky
DNA methyltransferase 3A (DNMT3A) is an enzyme involved in DNA methylation that is frequently mutated in human hematologic malignancies. We have previously shown that inactivation of Dnmt3a in hematopoietic cells results in chronic lymphocytic leukemia in mice. Here we show that 12% of Dnmt3a-deficient mice develop CD8+ mature peripheral T cell lymphomas (PTCL) and 29% of mice are affected by both diseases. 10% of Dnmt3a+/- mice develop lymphomas, suggesting that Dnmt3a is a haploinsufficient tumor suppressor in PTCL...
September 2016: PLoS Genetics
Staci L Haney, Garland M Upchurch, Jana Opavska, David Klinkebiel, Adams Kusi Appiah, Lynette M Smith, Tayla B Heavican, Javeed Iqbal, Shantaram Joshi, Rene Opavsky
Cytosine methylation of DNA is an epigenetic modification involved in the repression of genes that affect biological processes including hematopoiesis. It is catalyzed by DNA methyltransferases, one of which -DNMT3A- is frequently mutated in human hematologic malignancies. We have previously reported that Dnmt3a inactivation in hematopoietic stem cells results in chronic lymphocytic leukemia (CLL) and CD8-positive peripheral T cell lymphomas (PTCL) in EμSRα-tTA;Teto-Cre;Dnmt3a(fl/fl); Rosa26LOXP(EGFP/EGFP) (Dnmt3a(Δ/Δ)) mice...
September 28, 2016: Scientific Reports
Xianping Lu, Zhiqiang Ning, Zhibin Li, Haixiang Cao, Xinhao Wang
Peripheral T-cell lymphoma (PTCL) is a set of rare and highly heterogeneous group of mature T- and NK-cell neoplasms associated with poor outcomes and lack of standard and effective therapies. The total number of newly diagnosed cases of PTCL yearly in China is estimated about 50,000. Chidamide (CS055) is a novel and orally active benzamide class of histone deacetylase (HDAC) inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, the enzymes that are involved and play an important role in tumor initiation and development in both tumor cells and their surrounding micro-environment...
August 2016: Intractable & Rare Diseases Research
Claudius Irlé, Jonathan Weintraub
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas. Angioimmunoblastic T-cell lymphoma (AITL) is a common subtype of PTCL, and patients with AITL typically have a poor prognosis with limited treatment options. Clinical studies have demonstrated the activity of romidepsin, a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor, in patients with relapsed or refractory AITL. In the case presented herein, we describe a patient treated with single-agent romidepsin at first diagnosis of AITL, resulting in complete remission for over 2 years and leading to the use of maintenance dosing...
2016: Case Reports in Hematology
Pierre Mélard, Yamina Idrissi, Laetitia Andrique, Sandrine Poglio, Martina Prochazkova-Carlotti, Sabine Berhouet, Cécile Boucher, Elodie Laharanne, Edith Chevret, Anne Pham-Ledard, Andréa Carla De Souza Góes, Véronique Guyonnet-Duperat, Alice Bibeyran, François Moreau-Gaudry, Béatrice Vergier, Marie Beylot-Barry, Jean-Philippe Merlio, David Cappellen
Monoallelic 6p25.3 rearrangements associated with DUSP22 (Dual Specificity Phosphatase 22) gene silencing have been reported in CD30+ peripheral T-cell lymphomas (PTCL), mostly with anaplastic morphology and of cutaneous origin. However, the mechanism of second allele silencing and the putative tumor suppressor function of DUSP22 have not been investigated so far. Here, we show that the presence, in most individuals, of an inactive paralog hampers genetic and epigenetic evaluation of the DUSP22 gene. Identification of DUSP22-specific single-nucleotide polymorphisms haplotypes and fluorescence in situ hybridization and epigenetic characterization of the paralog status led us to develop a comprehensive strategy enabling reliable identification of DUSP22 alterations...
September 10, 2016: Oncotarget
Swetha Narla, S Annapurneswari, Ashok Parameswaran, Sheila Nair
Primary non-Hodgkin lymphomas of the oral region are rare, accounting for 3-5% of all malignant lesions. Of these, peripheral T-cell lymphomas (PTCLs) are extremely rare with only a few cases reported in literature. We describe a case of 50-year-old female who presented with an indurated lesion on the tongue. PTCL was diagnosed after immunohistochemical and T-cell receptor gene rearrangement analysis. Although PTCL of oral cavity is extremely rare, the possibility should always be considered in the differential diagnosis of T-lymphoid proliferations affecting this area...
May 2016: Journal of Oral and Maxillofacial Pathology: JOMFP
Kensei Tobinai
Recent clinical trials for T/NK-cell lymphomas are summarized herein, focusing on ATL and extranodal NK/T-cell lymphoma (ENKL). The outcomes of patients with these malignancies were the poorest among various peripheral T-cell lymphomas (PTCLs) in the International T-Cell Lymphoma Project. JCOG has conducted several clinical trials aimed at improving these poor outcomes. For aggressive ATL, JCOG is conducting a phase II trial of VCAP-AMP-VECP followed by allogeneic SCT. For localized ENKL, concurrent chemoradiotherapy has shown promising and durable efficacy in the phase I/II study...
August 2016: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Mamiko Sakata-Yanagimoto, Shigeru Chiba
The molecular pathogenesis of peripheral T-cell lymphoma (PTCL) has gradually been clarified in terms of genomic abnormalities. Insights into these genomic abnormalities have provided clues to understanding the pathogenesis of PTCL. Furthermore, the origins of lymphoma cells have been clarified by investigating the distribution of genomic abnormalities in tumor cells and non-tumor blood cells. Multistep tumorigenesis has been suggested to be a fundamental mechanism underlying the development of angioimmunoblastic T-cell lymphoma (AITL), a distinct subtype of PTCL: premalignant cells evolve from hematopoietic progenitors via mutations in epigenetic regulators...
August 2016: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Wei Zhang, Zi Wang, Yunping Luo, Dingrong Zhong, Yufeng Luo, Daobin Zhou
Peripheral T cell lymphoma (PTCL) is an aggressive form of non-Hodgkin's lymphoma characterized by a poor prognosis. In this study, we examined the prognostic value of two T-cell-specific transcription factors, GATA3 and T-bet, in PTCL, uncovered the pathogenesis of PTCL, and investigated new PTCL therapeutic targets. Samples from 109 PTCL patients were examined for expression of GATA3, T-bet and CD68. High GATA3 expression correlated with poor survival in PTCL patients and with tumor-associated macrophage (TAM) infiltration, as indicated by the presence of CD68-positive cells...
August 29, 2016: Oncotarget
Steven M Horwitz, Andrew D Zelenetz, Leo I Gordon, William G Wierda, Jeremy S Abramson, Ranjana H Advani, C Babis Andreadis, Nancy Bartlett, John C Byrd, Luis E Fayad, Richard I Fisher, Martha J Glenn, Thomas M Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T Hoppe, Mark S Kaminski, Christopher R Kelsey, Youn H Kim, Susan Krivacic, Ann S LaCasce, Matthew Lunning, Auayporn Nademanee, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A Saad, Lubomir Sokol, Lode J Swinnen, Julie M Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar, Pierluigi Porcu
Peripheral T-cell lymphomas (PTCLs) represent a relatively uncommon heterogeneous group of non-Hodgkin's lymphomas (NHLs) with an aggressive clinical course and poor prognosis. Anthracycline-based multiagent chemotherapy with or without radiation therapy followed by first-line consolidation with high-dose therapy followed by autologous stem cell rescue (HDT/ASCR) is the standard approach to most of the patients with newly diagnosed PTCL. Relapsed or refractory disease is managed with second-line systemic therapy followed by HDT/ASCR or allogeneic stem cell transplant, based on the patient's eligibility for transplant...
September 2016: Journal of the National Comprehensive Cancer Network: JNCCN
Zhaoyun Liu, Kai Ding, Lijuan Li, Hui Liu, Yihao Wang, Chunyan Liu, Rong Fu
Chidamide as a newly designed and synthesized histone deacetylase inhibitor induces an antitumor effect in various cancer, and it has been used in several clinical trials such as peripheral T cell lymphoma (PTCL). Here we demonstrate that Chidamide was able to increase the acetylation levels of histone H3 and decrease HDAC activity in MDS cell lines(SKM-1,MUTZ-1)and AML cell line(KG-1). In vitro, at low concentration (<250nM) of Chidamide inhibited cell proliferation and delayed G0/G1 cell cycle progression by down-regulating CDK2 and regulating p-P53 and P21 protein expression...
August 16, 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Jian Zheng, Hong Gao, Cheng-Yu Hong, Xiao-Ru Bai, Xue-Jun Lin, Xiao-Ling Li
OBJECTIVE: To analyze the clinical pathologic characteristics, diagnosis, treatment and outcome of patients with primary gastrointestinal non-Hodgkin's lymphoma(PGI-NHL). METHODS: The clinical and pathological features of 50 cases of PGI-NHL were analyzed retrospectively, the Kaplan-Meier was applied to estimate the survival time of all the patients. RESULTS: The median age of patients was 58 years old, the cases of male patient were more than that of femal...
August 2016: Zhongguo Shi Yan Xue Ye Xue za Zhi
S Sisó, P Marco-Salazar, P F Moore, B K Sturges, W Vernau, E R Wisner, A W Bollen, P J Dickinson, R J Higgins
Primary and secondary nervous system involvement occurs in 4% and 5%-12%, respectively, of all canine non-Hodgkin lymphomas. The recent new classification of canine malignant lymphomas, based on the human World Health Organization classification, has been endorsed with international acceptance. This histological and immunocytochemical classification provides a unique opportunity to study the histologic anatomic distribution patterns in the central and peripheral nervous system of these defined lymphoma subtypes...
August 10, 2016: Veterinary Pathology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"